Anemia Management
Diagnosis and Evaluation
- The American Society of Clinical Oncology recommends evaluating for iron deficiency by checking serum ferritin (<100 ng/mL indicates absolute deficiency) and transferrin saturation (TSAT <20% suggests functional deficiency) 1
- Patients with low hemoglobin (Hb) and hematocrit (Hct) should be assessed for underlying chronic diseases, such as cancer, autoimmune disorders, and chronic infections, to determine the cause of anemia 1
- The European Society for Medical Oncology suggests reviewing peripheral blood smear and considering bone marrow examination if indicated to determine the cause of anemia 1
Treatment
- The American College of Physicians recommends intravenous (IV) iron as first-line treatment for patients with absolute iron deficiency (serum ferritin <100 ng/mL) or functional iron deficiency (TSAT <20% and serum ferritin >100 ng/mL) 1
- The National Kidney Foundation recommends erythropoiesis-stimulating agents (ESAs) for patients with chemotherapy-induced anemia or chronic kidney disease with Hb below 10 g/dL, with a target Hb of 10-11 g/dL 2
- The American Society of Clinical Oncology recommends correcting iron deficiency before or during ESA therapy for functional iron deficiency, and monitoring Hb levels regularly to avoid rapid increases (>1 g/dL over 2 weeks) 1
- The European Society for Medical Oncology suggests that ESA therapy (epoetin or darbepoetin) is recommended for Hb <10 g/dL, with a target Hb not to exceed 12 g/dL due to increased thromboembolism risk 3
- The British Society for Haematology recommends RBC transfusion for Hb <7 g/dL, and considers transfusion based on symptoms and risk factors for Hb 7-10 g/dL 4
Transfusion Therapy
- The American Association of Blood Banks recommends using blood component therapy according to protocol for massive blood loss 4
- The European Society for Medical Oncology suggests considering automated red cell exchange (RCE) over simple transfusion to reduce iron overload for chronic transfusion, and automated RCE is preferred for severe acute chest syndrome 5
Treatment Strategies
- The Society of Critical Care Medicine recommends a restrictive strategy (Hb 7-8 g/dL) for most stable, non-bleeding patients, and a liberal strategy (Hb 9-10 g/dL) may be considered for patients with acute coronary syndrome or severe traumatic brain injury 6
Monitoring and Adverse Effects
- The American Society of Clinical Oncology recommends monitoring Hb/Hct regularly during treatment, and checking Hb every 2-4 weeks initially, then monthly for ESA therapy 1
- The European Society for Medical Oncology suggests monitoring for adverse effects of treatment, such as iron overload and ESA complications 1